Edesa Biotech CEO receives 18,677-unit stock grant

Nijhawan disclaims beneficial ownership of the additional company- and trust-held shares except to the extent of his pecuniary interest.

Available on EDGAR 11/05/2026 - 05:01 PM EST Accepted by SEC EDGAR 11/05/2026 - 05:01 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Edesa Biotech, Inc. Chief Executive Officer Pardeep Nijhawan acquired 18,677 restricted share units on November 4, 2026; the units vested in full upon grant under the issuer’s 2019 Equity Incentive Compensation Plan. His directly held Common Shares totaled 952,272 after the grant. The report also lists indirect Common Share positions through three companies and The New Nijhawan Family Trust 2015.

Insider Trade Summary

Grant/Award: 18,677 shares

Grant/Award 1 txn

Insider Nijhawan Pardeep

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Shares F1	18,677	$0.00	$0.00
Holding	Common Shares F2	--	--	--
Holding	Common Shares F3	--	--	--
Holding	Common Shares F2	--	--	--
Holding	Common Shares F2	--	--	--

Holdings After Transaction: Common Shares — 952,272 shares (Direct); Common Shares — 402,702 shares (Indirect, Held by Pardeep Nijhawan Medicine Professional Corporation); Common Shares — 32,609 shares (Indirect, Held by The New Nijhawan Family Trust 2015); Common Shares — 32,013 shares (Indirect, Held by The Digestive Health Clinic Inc.); Common Shares — 53,104 shares (Indirect, Held by 1968160Ontario Inc.)

Footnotes (3)

1. F1. Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.
2. F2. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
3. F3. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Key Figures

Restricted share units granted: 18,677 restricted share units Direct Common Shares after grant: 952,272 Common Shares Common Shares held by Pardeep Nijhawan Medicine Professional Corporation: 402,702 Common Shares +3 more

6 metrics

Restricted share units granted 18,677 restricted share units Grant on November 4, 2026; vested in full upon grant

Direct Common Shares after grant 952,272 Common Shares Directly held after the November 4, 2026 grant

Common Shares held by Pardeep Nijhawan Medicine Professional Corporation 402,702 Common Shares Position reported November 4, 2026

Common Shares held by The Digestive Health Clinic Inc. 32,013 Common Shares Position reported November 4, 2026

Common Shares held by 1968160 Ontario Inc. 53,104 Common Shares Position reported November 4, 2026

Common Shares held by The New Nijhawan Family Trust 2015 32,609 Common Shares Position reported November 4, 2026

Key Terms

restricted share units, vested in full, 2019 Equity Incentive Compensation Plan, beneficial ownership, +1 more

5 terms

restricted share units financial

"grant of restricted share units"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

vested in full financial

"which vested in full upon grant"

2019 Equity Incentive Compensation Plan financial

"pursuant to the Issuer's 2019 Equity Incentive Compensation Plan"

beneficial ownership regulatory

"disclaims beneficial ownership of these securities"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

pecuniary interest regulatory

"except to the extent of his pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many restricted share units did EDSA’s CEO receive?

Pardeep Nijhawan acquired 18,677 restricted share units on November 4, 2026. The units vested in full upon grant under Edesa Biotech’s 2019 Equity Incentive Compensation Plan.

What EDSA shares were reported through Pardeep Nijhawan’s related entities and trust?

The report lists 402,702 Common Shares held by Pardeep Nijhawan Medicine Professional Corporation, 32,013 by The Digestive Health Clinic Inc., 53,104 by 1968160 Ontario Inc., and 32,609 by The New Nijhawan Family Trust 2015. The footnotes state that the three companies are wholly owned by Nijhawan and that he is a co-trustee of the trust; he disclaims beneficial ownership except to the extent of his pecuniary interest.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nijhawan Pardeep

(Last) (First) (Middle)

333 BAY STREET, SUITE 2400

(Street)

TORONTO M5H 2T6

(City) (State) (Zip)

ONTARIO, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edesa Biotech, Inc. [ EDSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	11/04/2026		A		18,677(1)	A	$0(1)	952,272	D
Common Shares								402,702	I	Held by Pardeep Nijhawan Medicine Professional Corporation(2)
Common Shares								32,609	I	Held by The New Nijhawan Family Trust 2015(3)
Common Shares								32,013	I	Held by The Digestive Health Clinic Inc.(2)
Common Shares								53,104	I	Held by 1968160Ontario Inc.(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects a grant of restricted share units, which vested in full upon grant, pursuant to the Issuer's 2019 Equity Incentive Compensation Plan.

2. Each of Pardeep Medicine Professional Corporation, The Digestive Health Clinic Inc. and 1968160 Ontario Inc. are wholly-owned by Reporting Person. Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

3. Reporting Person is a co-trustee of The New Nijhawan Family Trust 2015. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

	/s/ Peter J. Weiler, Attorney-in-Fact for Pardeep Nijhawan	11/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)